To Be Discontinued Injection Hematology
Busulfan Injection · 322 days since initial FDA posting
Brand: BUSULFAN
FDA lists Busulfan Injection as To Be Discontinued (Mylan Institutional, a Viatris Company).
No availability text on this FDA row.
Busulfan Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Busulfan Injection
- Manufacturer
- Mylan Institutional, a Viatris Company
- Dosage Form
- Injection
- Presentation
- Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08)
- Package NDC
- 67457-893-08
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Oct 24, 2025
- Last Updated
- Oct 24, 2025
- Therapeutic Category
- Hematology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug.
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.